Medicare Enrolled
Dr. Ronald Drengler, M.D.
Medical Oncology · San Antonio, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Drengler from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Drengler?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Drengler
Dr. Ronald Drengler is a medical oncology specialist in San Antonio, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Drengler performed 223,535 Medicare services across 3,891 unique beneficiaries.
Between the years covered by Open Payments, Dr. Drengler received a total of $7,743 from 69 pharmaceutical and/or device companies across 370 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Drengler is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 2% volume in TX
$7,743 industry payments
Medicare Practice Summary
Medicare Utilization ↗223,535
Medicare services
Top 2% in TX for medical oncology
3,891
Unique beneficiaries
$17
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~11,765 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Oxaliplatin chemotherapy injection | 52,550 | $0 | $5 |
| Nivolumab injection (Opdivo) | 48,240 | $23 | $91 |
| Iron infusion (Injectafer) | 47,700 | $1 | $3 |
| Pembrolizumab injection (Keytruda) | 21,000 | $43 | $165 |
| Injection, eflapegrastim-xnst, 0.1 mg | 8,580 | $25 | $95 |
| Denosumab injection (Prolia/Xgeva) | 6,900 | $18 | $71 |
| Injection, ipilimumab, 1 mg | 6,770 | $127 | $217 |
| Injection, atropine sulfate, 0.01 mg | 4,080 | $0 | $1 |
| Epoetin alfa injection (Retacrit) for anemia | 2,760 | $6 | $24 |
| Dexamethasone injection (steroid) | 2,716 | $0 | $0 |
| Injection, leucovorin calcium, per 50 mg | 1,716 | $3 | $13 |
| Injection, fluorouracil, 500 mg | 1,426 | $2 | $7 |
| Lactate dehydrogenase (enzyme) level | 1,368 | $6 | $18 |
| Injection, irinotecan, 20 mg | 1,316 | $2 | $37 |
| Comprehensive metabolic blood panel | 1,233 | $10 | $32 |
| Epoetin alfa injection (Procrit) for anemia | 1,200 | $6 | $21 |
| Complete blood count (CBC) with differential | 1,118 | $8 | $23 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 876 | $92 | $645 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 762 | $22 | $86 |
| Anti-nausea injection (ondansetron/Zofran) | 760 | $0 | $2 |
| Blood draw (venipuncture) | 734 | $8 | $14 |
| Injection, potassium chloride, per 2 meq | 715 | $0 | $0 |
| Office visit, established patient (30-39 min) | 665 | $97 | $373 |
| Administration of chemotherapy into vein, 1 hour or less | 660 | $99 | $377 |
| Injection, magnesium sulfate, per 500 mg | 498 | $1 | $2 |
| Drug injection, under skin or into muscle | 456 | $11 | $47 |
| Magnesium level test | 453 | $7 | $20 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 375 | $3 | $46 |
| Injection of additional new drug or substance into vein | 344 | $12 | $58 |
| Administration of additional new drug or substance into vein, 1 hour or less | 335 | $49 | $205 |
| Carcinoembryonic antigen (cea) protein level | 319 | $19 | $57 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 | 317 | $20 | $62 |
| Administration of chemotherapy into vein, each additional hour | 307 | $21 | $90 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 220 | $337 | $1,315 |
| Office visit, established patient (20-29 min) | 217 | $66 | $263 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 198 | $48 | $185 |
| Free thyroxine (T4) test | 195 | $9 | $27 |
| Thyroid hormone, t3 measurement, free | 194 | $16 | $51 |
| Office visit, established patient, complex (40-54 min) | 192 | $131 | $523 |
| Infusion, normal saline solution , 1000 cc | 192 | $2 | $19 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 184 | $126 | $419 |
| Injection, diphenhydramine hcl, up to 50 mg | 150 | $1 | $3 |
| Amylase (enzyme) level | 148 | $6 | $19 |
| Lipase (fat enzyme) level | 148 | $7 | $21 |
| Complete blood count (CBC), automated | 143 | $6 | $19 |
| Infusion into a vein for hydration, 31-60 minutes | 137 | $25 | $137 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 129 | $16 | $60 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 125 | 120 | $20 | $62 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 115 | $15 | $58 |
| Iron level test | 113 | $6 | $19 |
| Iron binding capacity test | 113 | $9 | $26 |
| Ferritin level test (iron stores) | 111 | $13 | $41 |
| Infusion into a vein for hydration, each additional hour | 98 | $10 | $42 |
| Irrigation of implanted venous access drug delivery device | 85 | $19 | $73 |
| Unclassified drugs | 85 | $1 | $2 |
| Hospital follow-up visit, moderate complexity | 80 | $59 | $232 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 79 | $20 | $62 |
| Urinalysis, manual | 78 | $3 | $10 |
| Vitamin B-12 level test | 76 | $15 | $45 |
| Red blood count, automated test | 75 | $4 | $12 |
| Creatine kinase (cardiac enzyme) level, total | 69 | $6 | $20 |
| Application of on-body injector for under skin injection | 69 | $14 | $54 |
| Administration of additional new drug or substance into vein using push technique | 67 | $43 | $160 |
| Troponin (protein) analysis, quantitative | 47 | $12 | $37 |
| New patient office visit, complex (60-74 min) | 47 | $172 | $651 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 46 | $4 | $16 |
| Phosphate level test | 41 | $5 | $14 |
| PSA test (prostate cancer screening) | 39 | $18 | $55 |
| Immunoglobulin level test | 36 | $9 | $28 |
| Thyroid stimulating hormone (TSH) test | 35 | $16 | $50 |
| Hospital follow-up visit, high complexity | 17 | $93 | $349 |
| Uric acid level test | 16 | $4 | $14 |
| Prothrombin time test (blood clotting) | 16 | $4 | $13 |
| Detection test by immunoassay technique for hepatitis b surface antigen | 15 | $10 | $31 |
| Injection of drug or substance into vein | 14 | $27 | $131 |
| Thyroid hormone, t3 measurement, total | 13 | $14 | $43 |
| Hepatitis b core antibody measurement | 13 | $12 | $36 |
| New patient office visit (45-59 min) | 11 | $130 | $529 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
22.2% high complexity
73.7% medium
4.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$7,743
Total received (2018-2024)
Avg $1,106/year across 7 years
Top 39% in TX for medical oncology
69
Companies
370
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,405 (95.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$338 (4.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,829
2023
$1,597
2022
$182
2021
$83
2020
$120
2019
$1,158
2018
$1,773
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$1,156
Janssen Biotech, Inc.
$485
AstraZeneca Pharmaceuticals LP
$415
Genentech USA, Inc.
$407
PFIZER INC.
$332
Novartis Pharmaceuticals Corporation
$328
Regeneron Healthcare Solutions, Inc.
$302
Daiichi Sankyo Inc.
$241
Celgene Corporation
$240
Takeda Pharmaceuticals U.S.A., Inc.
$237
Tempus AI, Inc
$236
Astellas Pharma US Inc
$208
Lilly USA, LLC
$196
Amgen Inc.
$182
Merck Sharp & Dohme LLC
$168
AbbVie, Inc.
$146
Karyopharm Therapeutics Inc.
$145
Adaptive Biotechnologies Corporation
$144
Medtronic, Inc.
$142
Bayer HealthCare Pharmaceuticals Inc.
$108
Puma Biotechnology, Inc.
$105
Sumitomo Pharma America, Inc.
$102
Incyte Corporation
$98
Teva Pharmaceuticals USA, Inc.
$78
GENZYME CORPORATION
$72
Alexion Pharmaceuticals, Inc.
$71
Gilead Sciences, Inc.
$67
GI Supply, Inc.
$62
Agios Pharmaceuticals, Inc.
$60
Seagen Inc.
$58
Immunocore Limited
$57
Deciphera Pharmaceuticals Inc.
$55
TESARO, Inc.
$51
EMD Serono, Inc.
$51
Seattle Genetics, Inc.
$50
Merck Sharp & Dohme Corporation
$49
MorphoSys, US Inc.
$49
Foundation Medicine, Inc.
$48
JAZZ PHARMACEUTICALS INC.
$46
Pharmacyclics LLC, An AbbVie Company
$42
Heron Therapeutics, Inc.
$41
ADC Therapeutics America, Inc.
$39
Mirati Therapeutics, Inc.
$36
Boehringer Ingelheim Pharmaceuticals, Inc.
$35
Kyowa Kirin, Inc.
$33
Medtronic USA, Inc.
$28
GlaxoSmithKline, LLC.
$27
Exelixis Inc.
$26
Kite Pharma, Inc.
$25
Eisai Inc.
$24
SOBI, INC
$23
Bayer Healthcare Pharmaceuticals Inc.
$23
Sirtex Medical Inc
$21
Iovance Biotherapeutics, Inc.
$21
AbbVie Inc.
$21
Allergan Inc.
$20
PUMA BIOTECHNOLOGY, INC.
$20
SpringWorks Therapeutics, Inc.
$20
Genmab U.S., Inc.
$19
TAIHO ONCOLOGY, INC.
$19
SERVIER PHARMACEUTICALS LLC
$19
Ipsen Biopharmaceuticals, Inc
$18
Secura Bio, Inc.
$16
Spectrum Pharmaceuticals Inc.
$15
Taiho Oncology, Inc.
$13
Azurity Pharmaceuticals, Inc.
$13
AMAG Pharmaceuticals, Inc.
$12
Array BioPharma Inc.
$11
Janssen Pharmaceuticals, Inc
$11
Top 3 companies account for 26.6% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · AUGTYRO · Aliqopa · Amtagvi · Avastin · BENDEKA · BLENREP · BOSULIF · BRAFTOVI · Bavencio · Braftovi · CABOMETYX · CALQUENCE · CINVANTI · COPIKTRA · CYRAMZA · Cabometyx · Columvi · Creon · DARZALEX · DOPTELET · EMPLICITI · ENHERTU · ENJAYMO · ERLEADA · Enhertu · Epkinly · Erleada · FARESTON · FERAHEME · FOUNDATIONONE · FRUZAQLA · Fabhalta · GAZYVA · GILOTRIF · IBRANCE · ICLUSIG · IMFINZI · INJECTAFER · Imbruvica · JADENU · JAKAFI · JEVTANA · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LINZESS · LONSURF · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MYLOTARG · NINLARO · Nerlynx · Neulasta · Nplate · OGSIVEO · OPDIVO · OPDUALAG · ORGOVYX · PADCEV · POTELIGEO · PROMACTA · PYRUKYND · Padcev · Perjeta · Pomalyst · QINLOCK · REBLOZYL · ROLVEDON · RYBREVANT · Revlimid · Rituxan Hycela · SIGNIA · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SUTENT · SYNCHROMED · Stivarga · TAGRISSO · TECENTRIQ · TECVAYLI · TIBSOVO · TUMOR LYSIS SYNDROME - DISEASE · Tecentriq · Tibsovo · ULTOMIRIS · VENCLEXTA · VERZENIO · VIVIMUSTA · VOTRIENT · Venclexta · Vitrakvi · Vyloy · WELIREG · XALKORI · XARELTO · XOSPATA · XPOVIO · XTANDI · Xofigo · Xospata · Yescarta · ZEJULA · ZEPZELCA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $3 per 100 Medicare services performed
Geographic Context
Medical oncologists within 10 mi
37
Per 100K population
1.8
County median income
$70,571
Nearest hospital
UNIVERSITY HEALTH SYSTEM
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Drengler is a mixed practice specialist, with above-average Medicare volume (top 2% in TX), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Drengler experienced with oxaliplatin chemotherapy injection?
Based on Medicare claims data, Dr. Drengler performed 52,550 oxaliplatin chemotherapy injection services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Drengler receive payments from pharmaceutical companies?
Yes. Dr. Drengler received a total of $7,743 from 69 companies across 370 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Drengler's costs compare to other medical oncologists in San Antonio?
Dr. Drengler's average Medicare payment per service is $17. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Drengler) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in San Antonio
Browse medical oncologists in San Antonio ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in TX
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in TX
Which TX medical oncologists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology